CR20150056A - Derivados de azaindol - Google Patents

Derivados de azaindol

Info

Publication number: CR20150056A
Authority: CR; Costa Rica
Prior art keywords: formula; azaindol; derivatives; disorders; compounds
Prior art date: 2012-07-10

Application number

CR20150056A

Other languages

English (en)

Spanish (es)

Inventor

Edcon Chang

Wolfgang Reinhard Ludwig Notz

Michael B Wallace

Original Assignee

Takeda Pharmaceutical

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-07-10

Filing date

2015-02-06

Publication date

2015-05-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48795966&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20150056(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-02-06 Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical

2015-05-25 Publication of CR20150056A publication Critical patent/CR20150056A/es

Links

150000001875 compounds Chemical class 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 abstract 1
208000024172 Cardiovascular disease Diseases 0.000 abstract 1
108091007960 PI3Ks Proteins 0.000 abstract 1
201000011529 cardiovascular cancer Diseases 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
208000026278 immune system disease Diseases 0.000 abstract 1
239000000463 material Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Immunology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Diabetes (AREA)
Hematology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Otolaryngology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

CR20150056A 2012-07-10 2015-02-06 Derivados de azaindol CR20150056A (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261670116P	2012-07-10	2012-07-10
PCT/US2013/049612 WO2014011568A1 (fr)	2012-07-10	2013-07-08	Dérivés d'azaindole agissant comme inhibiteur de pi3k

Publications (1)

Publication Number	Publication Date
CR20150056A true CR20150056A (es)	2015-05-25

Family

ID=48795966

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CR20150056A CR20150056A (es)	2012-07-10	2015-02-06	Derivados de azaindol

Country Status (26)

Country	Link
US (2)	US8835420B2 (fr)
EP (1)	EP2872507A1 (fr)
JP (1)	JP2015522074A (fr)
KR (1)	KR20150031334A (fr)
CN (1)	CN104619708A (fr)
AP (1)	AP2015008236A0 (fr)
AR (1)	AR092347A1 (fr)
AU (1)	AU2013288895A1 (fr)
BR (1)	BR112015000386A2 (fr)
CA (1)	CA2878502A1 (fr)
CO (1)	CO7280475A2 (fr)
CR (1)	CR20150056A (fr)
DO (1)	DOP2015000002A (fr)
EA (1)	EA201590183A1 (fr)
HK (1)	HK1210771A1 (fr)
IL (1)	IL236535A0 (fr)
MA (1)	MA37831B1 (fr)
MX (1)	MX2015000107A (fr)
NZ (1)	NZ704160A (fr)
PE (1)	PE20150754A1 (fr)
PH (1)	PH12015500063B1 (fr)
SG (1)	SG11201500063UA (fr)
TN (1)	TN2015000005A1 (fr)
TW (1)	TW201414734A (fr)
UY (1)	UY34893A (fr)
WO (1)	WO2014011568A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
LT2718270T (lt)	2011-06-10	2022-08-10	Merck Patent Gmbh	Pirimidino ir piridino junginių, turinčių btk inhibitorinį aktyvumą, kompozicijos ir gamybos būdai
WO2015106014A1 (fr) *	2014-01-09	2015-07-16	Takeda Pharmaceutical Company Limited	Dérivés d'azaindole
AR099052A1 (es)	2014-01-09	2016-06-29	Takeda Pharmaceuticals Co	Derivados de azaindol
ES2749679T3 (es)	2014-10-22	2020-03-23	Bristol Myers Squibb Co	Compuestos de pirrolotriazina amina sustituidos como inhibidores de PI3k
WO2016064957A1 (fr)	2014-10-22	2016-04-28	Bristol-Myers Squibb Company	Composés amine hétéroaryles bicycliques utilisés comme inhibiteurs de la pi3k
US9997391B2 (en) *	2015-10-19	2018-06-12	QROMIS, Inc.	Lift off process for chip scale package solid state devices on engineered substrate
LT3371165T (lt) *	2015-11-04	2022-05-10	Merck Patent Gmbh	Btk inhibitorius, naudojamas vėžiui gydyti
NZ741294A (en) *	2015-11-17	2023-07-28	Merck Patent Gmbh	Methods for treating multiple sclerosis using pyrimidine and pyridine compounds with btk inhibitory activity
CA3124815A1 (en)	2016-03-05	2017-09-14	Hangzhou Zhengxiang Pharmaceuticals Co., Ltd.	Quinoline analogs as phosphatidylinositol 3-kinase inhibitors
US10755986B2 (en) *	2016-03-29	2020-08-25	QROMIS, Inc.	Aluminum nitride based Silicon-on-Insulator substrate structure
CN107964018A (zh) *	2016-10-19	2018-04-27	中国人民解放军军事医学科学院毒物药物研究所	取代嘌呤酮类衍生物及其医药用途
WO2020224626A1 (fr) *	2019-05-08	2020-11-12	浙江同源康医药股份有限公司	Composé utilisé comme inhibiteur de kinase et son application
CN112794851B (zh) *	2021-01-26	2022-08-23	复旦大学	3-(吡啶-3基)-7-氮杂吲哚衍生物PI3Kδ抑制剂及其制备方法与应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR0166088B1 (ko)	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en)	1990-01-23	1994-12-27	University Of Kansas	Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en)	1995-09-15	1995-11-15	Pfizer Ltd	Pharmaceutical formulations
GB9711643D0 (en)	1997-06-05	1997-07-30	Janssen Pharmaceutica Nv	Glass thermoplastic systems
US6187777B1 (en)	1998-02-06	2001-02-13	Amgen Inc.	Compounds and methods which modulate feeding behavior and related diseases
US6667300B2 (en)	2000-04-25	2003-12-23	Icos Corporation	Inhibitors of human phosphatidylinositol 3-kinase delta
MXPA02010618A (es)	2000-04-25	2004-05-05	Icos Corp	Inhibidores de fosfatidilinositol 3-quinasa delta.
US20020183292A1 (en)	2000-10-31	2002-12-05	Michel Pairet	Pharmaceutical compositions based on anticholinergics and corticosteroids
US6806272B2 (en)	2001-09-04	2004-10-19	Boehringer Ingelheim Pharma Kg	Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
US7348337B2 (en)	2002-05-28	2008-03-25	Bristol-Myers Squibb Company	Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
US6900206B2 (en)	2002-06-20	2005-05-31	Bristol-Myers Squibb Company	Indole, azaindole and related heterocyclic sulfonylureido piperazine derivatives
US6861422B2 (en)	2003-02-26	2005-03-01	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
DE602004027288D1 (en)	2003-09-08	2010-07-01	Aventis Pharma Inc	Thienopyrazole
BRPI0417323A (pt)	2003-12-22	2007-03-27	Memory Pharm Corp	indóis, 1h-indazóis, 1,2-benzisoxazóis, e 1,2-benzisotiazóis, composto, composição farmacêutica e usos dos mesmos
JP2007534692A (ja)	2004-04-22	2007-11-29	メモリー・ファーマシューティカルズ・コーポレイション	インドール、１ｈ−インダゾール、１，２−ベンズイソキサゾール、１，２−ベンゾイソチアゾール、ならびにその調製および使用
GB0415364D0 (en)	2004-07-09	2004-08-11	Astrazeneca Ab	Pyrimidine derivatives
DE102004034623A1 (de)	2004-07-16	2006-02-02	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue 6-Formyl-tetrahydropteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7759485B2 (en)	2004-08-14	2010-07-20	Boehringer Ingelheim International Gmbh	Process for the manufacture of dihydropteridinones
US20060035903A1 (en)	2004-08-14	2006-02-16	Boehringer Ingelheim International Gmbh	Storage stable perfusion solution for dihydropteridinones
JP2008510771A (ja)	2004-08-27	2008-04-10	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	ジヒドロプテリジノン、その製造方法および医薬薬剤としてのその使用
DE102004058337A1 (de)	2004-12-02	2006-06-14	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
FR2878849B1 (fr)	2004-12-06	2008-09-12	Aventis Pharma Sa	Indoles substitues, compositions les contenant, procede de fabrication et utilisation
JP2010501537A (ja)	2006-08-24	2010-01-21	アストラゼネカアクチボラグ	増殖性障害の治療に有用なモルホリノピリミジン誘導体
CL2007003444A1 (es)	2006-11-30	2008-06-27	Genentech Inc	Compuestos derivados de pirrolo[3,2-c]piridina; composicion farmaceutica; y uso en el tratamiento de un trastorno hiperproliferativo o una enfermedad inflamatoria.
WO2008157179A2 (fr)	2007-06-12	2008-12-24	Genentech, Inc.	Azaindoles n-substitués et procédés d'utilisation
CA2695583A1 (fr)	2007-08-13	2009-02-19	Metabasis Therapeutics, Inc.	Nouveaux activateurs de glucokinase
WO2010036380A1 (fr)	2008-09-26	2010-04-01	Intellikine, Inc.	Inhibiteurs hétérocycliques de kinases
WO2010129467A1 (fr)	2009-05-04	2010-11-11	Plexxikon, Inc.	Composés et procédés pour inhiber la rénine, et indications associées
US8754089B2 (en)	2009-06-25	2014-06-17	Amgen Inc.	Heterocyclic compounds and their uses
UY32743A (es) *	2009-06-25	2010-12-31	Amgen Inc	Compuestos heterocíclicos y sus usos
EP2448938B9 (fr)	2009-06-29	2015-06-10	Incyte Corporation	Pyrimidinones comme inhibiteurs de pi3k
WO2012148548A1 (fr)	2011-02-25	2012-11-01	Takeda Pharmaceutical Company Limited	Oxazinoptéridines et oxazonoptéridinones n-substituées
AR099052A1 (es) *	2014-01-09	2016-06-29	Takeda Pharmaceuticals Co	Derivados de azaindol

2013
- 2013-07-05 TW TW102124297A patent/TW201414734A/zh unknown
- 2013-07-05 UY UY0001034893A patent/UY34893A/es not_active Application Discontinuation
- 2013-07-08 AP AP2015008236A patent/AP2015008236A0/xx unknown
- 2013-07-08 CA CA2878502A patent/CA2878502A1/fr not_active Abandoned
- 2013-07-08 JP JP2015521701A patent/JP2015522074A/ja active Pending
- 2013-07-08 WO PCT/US2013/049612 patent/WO2014011568A1/fr not_active Ceased
- 2013-07-08 HK HK15111423.7A patent/HK1210771A1/xx unknown
- 2013-07-08 KR KR20157003555A patent/KR20150031334A/ko not_active Withdrawn
- 2013-07-08 BR BR112015000386A patent/BR112015000386A2/pt not_active Application Discontinuation
- 2013-07-08 US US13/937,081 patent/US8835420B2/en not_active Expired - Fee Related
- 2013-07-08 EP EP13737976.4A patent/EP2872507A1/fr not_active Withdrawn
- 2013-07-08 EA EA201590183A patent/EA201590183A1/ru unknown
- 2013-07-08 AU AU2013288895A patent/AU2013288895A1/en not_active Abandoned
- 2013-07-08 MA MA37831A patent/MA37831B1/fr unknown
- 2013-07-08 PE PE2015000013A patent/PE20150754A1/es not_active Application Discontinuation
- 2013-07-08 NZ NZ704160A patent/NZ704160A/en not_active IP Right Cessation
- 2013-07-08 SG SG11201500063UA patent/SG11201500063UA/en unknown
- 2013-07-08 MX MX2015000107A patent/MX2015000107A/es unknown
- 2013-07-08 AR ARP130102427A patent/AR092347A1/es unknown
- 2013-07-08 CN CN201380043657.XA patent/CN104619708A/zh active Pending
2014
- 2014-08-04 US US14/451,254 patent/US20140343033A1/en not_active Abandoned
- 2014-12-31 IL IL236535A patent/IL236535A0/en unknown
2015
- 2015-01-07 DO DO2015000002A patent/DOP2015000002A/es unknown
- 2015-01-07 TN TNP2015000005A patent/TN2015000005A1/fr unknown
- 2015-01-09 PH PH12015500063A patent/PH12015500063B1/en unknown
- 2015-02-04 CO CO15021949A patent/CO7280475A2/es unknown
- 2015-02-06 CR CR20150056A patent/CR20150056A/es unknown

Also Published As

Publication number	Publication date
PH12015500063A1 (en)	2015-03-02
BR112015000386A2 (pt)	2017-06-27
JP2015522074A (ja)	2015-08-03
DOP2015000002A (es)	2015-04-15
IL236535A0 (en)	2015-02-26
UY34893A (es)	2014-02-28
TN2015000005A1 (en)	2016-06-29
AU2013288895A1 (en)	2015-02-12
HK1210771A1 (zh)	2016-05-06
CA2878502A1 (fr)	2014-01-16
AP2015008236A0 (en)	2015-01-31
EP2872507A1 (fr)	2015-05-20
US20140018344A1 (en)	2014-01-16
MX2015000107A (es)	2015-04-14
PH12015500063B1 (en)	2015-03-02
SG11201500063UA (en)	2015-03-30
EA201590183A1 (ru)	2015-06-30
US8835420B2 (en)	2014-09-16
MA37831A1 (fr)	2018-02-28
KR20150031334A (ko)	2015-03-23
NZ704160A (en)	2017-01-27
PE20150754A1 (es)	2015-05-15
WO2014011568A1 (fr)	2014-01-16
US20140343033A1 (en)	2014-11-20
TW201414734A (zh)	2014-04-16
CO7280475A2 (es)	2015-05-29
CN104619708A (zh)	2015-05-13
AR092347A1 (es)	2015-04-15
MA37831B1 (fr)	2018-09-28

Publication	Publication Date	Title
CR20150056A (es)	2015-05-25	Derivados de azaindol
UY37900A (es)	2019-04-30	Nuevos derivados de rapamicina
DOP2016000276A (es)	2017-02-28	2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
CY1118739T1 (el)	2017-07-12	Ενωσεις αμφι(φθoρoαλκυλ)-1,4-βενζoδιαζεπινoνης ως αναστολεις toy notch
UY33921A (es)	2012-09-28	Oxazinopteridinas y oxazinoptiridinonas n-sustituidas
CY1118379T1 (el)	2017-06-28	Αναστολεις ιου ηπατιτιδας c
MX2015011533A (es)	2016-02-03	Derivados de triazolona de piridinilo y piridinilo fusionado.
MX2015011273A (es)	2015-12-03	Uso de derivados de pirazolopirimidina para el tratamiento de trastornos relacio nados con la fosfoinositida 3-cinasa delta.
DOP2014000203A (es)	2015-02-15	Compuestos de heterociclilo
ECSP15012804A (es)	2015-12-31	Alcoxipirazoles como activadores de guanilato ciclasa soluble
UY34917A (es)	2014-01-31	Inhibidores de la producción de leucotrieno-a4-hidrolasa (lta4h), composiciones farmacéuticas que los contienen y proceso para su preparación
MX2020004283A (es)	2021-10-21	Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.
CR20140399A (es)	2014-10-07	Pirrolidina-2-carboxamidas sustituidas
DOP2017000034A (es)	2017-03-15	Compuestos de imidazopiridazina
UY35551A (es)	2014-10-31	Derivados heteroarilos como inhibidores de aldosterona sintasa
MX2019011286A (es)	2019-12-19	Carboxamidas heteroaromaticas sustituidas de piperidinilo y piperazinilo como moduladores de gpr6.
MX2017001603A (es)	2017-09-07	Derivados de piperazina como moduladores de los receptores x del higado.
GT201400242A (es)	2015-08-27	"nuevos compuestos de pirazol"
UY35945A (es)	2015-08-31	Derivados de azaindol
ECSP18056196A (es)	2018-08-31	Derivados de indano
DOP2017000138A (es)	2017-07-31	Derivados de fumagilol
MX2019014940A (es)	2020-02-19	Moduladores de tetrahidropiridopirazinas del receptor 6 acoplado a la proteina g (gpr6).